Milestone Pharmaceuticals Inc. (MIST)

1,6400 +0,0400 (+2,50%) Börsenschluss: 04:00PM EDT

Milestone Pharmaceuticals Inc.

1111 Dr. Frederik-Philips Boulevard
Suite 420
Montreal, QC H4M 2X6
Canada
514 336 0444
https://www.milestonepharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 47

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Joseph G. Oliveto M.B.A.	CEO, President & Director	905,71k	N/A	1968
Mr. Amit Hasija	CFO & Executive VP of Corporate Development	603,18k	N/A	1973
Dr. David B. Bharucha FACC, M.D., Ph.D.	Chief Medical Officer	440,67k	N/A	1962
Dr. Philippe Douville M.B.A., Ph.D.	Founder, Strategic Advisor & Member of Scientific Advisory Board	N/A	N/A	1962
Ms. Kim Fox	Vice President of Communications	N/A	N/A	N/A
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.	Chief Medical Advisor & Member of the Scientific Advisory Board	N/A	N/A	1956
Dr. Guy Rousseau	SVP of Regulatory Affairs and Quality Management	N/A	N/A	N/A
Ms. Anita Holz	VP & Head of Medical Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Corporate Governance

Milestone Pharmaceuticals Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.